GenFleet broadens its RAS ambitions
And Treeline and HengRui also get in on the pan-RAS act.
DualityBio tries to float again
The group expects to raise nearly $170m.
Avenzo follows Bristol’s lead
The private group taps DualityBio for an EGFR x HER3 ADC.
Cell cycle niche seeks clinical validation
Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.
